127 related articles for article (PubMed ID: 26393486)
1. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis.
Masi A; Lampit A; Glozier N; Hickie IB; Guastella AJ
Transl Psychiatry; 2015 Sep; 5(9):e640. PubMed ID: 26393486
[TBL] [Abstract][Full Text] [Related]
2. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
Siafis S; Çıray O; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
Mol Autism; 2020 Aug; 11(1):66. PubMed ID: 32847616
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive systematic review and meta-analysis of pharmacological and dietary supplement interventions in paediatric autism: moderators of treatment response and recommendations for future research.
Masi A; Lampit A; DeMayo MM; Glozier N; Hickie IB; Guastella AJ
Psychol Med; 2017 May; 47(7):1323-1334. PubMed ID: 28091344
[TBL] [Abstract][Full Text] [Related]
4. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis.
Fraguas D; Díaz-Caneja CM; Pina-Camacho L; Moreno C; Durán-Cutilla M; Ayora M; González-Vioque E; de Matteis M; Hendren RL; Arango C; Parellada M
Pediatrics; 2019 Nov; 144(5):. PubMed ID: 31586029
[TBL] [Abstract][Full Text] [Related]
5. Placebo-like response in absence of treatment in children with Autism.
Jones RM; Carberry C; Hamo A; Lord C
Autism Res; 2017 Sep; 10(9):1567-1572. PubMed ID: 28401674
[TBL] [Abstract][Full Text] [Related]
6. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
[TBL] [Abstract][Full Text] [Related]
7. Supplement intervention associated with nutritional deficiencies in autism spectrum disorders: a systematic review.
Li YJ; Li YM; Xiang DX
Eur J Nutr; 2018 Oct; 57(7):2571-2582. PubMed ID: 28884333
[TBL] [Abstract][Full Text] [Related]
8. Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems.
Brugha TS; Doos L; Tempier A; Einfeld S; Howlin P
Int J Methods Psychiatr Res; 2015 Jun; 24(2):99-115. PubMed ID: 26077193
[TBL] [Abstract][Full Text] [Related]
9. Clinician- versus caregiver-rated scales as outcome measures of repetitive-restricted behaviors in clinical trials of autism: A systematic review and meta-analysis.
Siafis S; Leucht S
Eur Neuropsychopharmacol; 2023 May; 70():56-62. PubMed ID: 36870216
[TBL] [Abstract][Full Text] [Related]
10. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.
Tobe R; Zhu Y; Gleissl T; Rossomanno S; Veenstra-VanderWeele J; Smith J; Hollander E
Neuropsychopharmacology; 2023 Jul; 48(8):1201-1216. PubMed ID: 37045991
[TBL] [Abstract][Full Text] [Related]
11. Placebo effects in children with autism spectrum disorder.
Curie A; Oberlander TF; Jensen KB
Dev Med Child Neurol; 2023 Oct; 65(10):1316-1320. PubMed ID: 36917698
[TBL] [Abstract][Full Text] [Related]
12. The effect of dietary supplements on clinical aspects of autism spectrum disorder: A systematic review of the literature.
Gogou M; Kolios G
Brain Dev; 2017 Sep; 39(8):656-664. PubMed ID: 28438367
[TBL] [Abstract][Full Text] [Related]
13. Dietary Supplement for Core Symptoms of Autism Spectrum Disorder: Where Are We Now and Where Should We Go?
Li YJ; Ou JJ; Li YM; Xiang DX
Front Psychiatry; 2017; 8():155. PubMed ID: 28878697
[TBL] [Abstract][Full Text] [Related]
14. Placebo eff ects in psychiatry: mediators and moderators.
Weimer K; Colloca L; Enck P
Lancet Psychiatry; 2015 Mar; 2(3):246-57. PubMed ID: 25815249
[TBL] [Abstract][Full Text] [Related]
15. Paring down the placebo response.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(12):807-808. PubMed ID: 27895331
[No Abstract] [Full Text] [Related]
16. Targeting cholinergic and endocannabinoid system as a therapeutic intervention for core asd associated phenotypes in autism model: a systematic review.
Udodi PS; Anyanwu GE; Udodi ER; Ezejindu DN
Trends Psychiatry Psychother; 2024 Jun; ():. PubMed ID: 38885129
[TBL] [Abstract][Full Text] [Related]
17. Placebo effects and participant heterogeneity in clinical trials of autism spectrum disorder.
Loth E
Lancet Psychiatry; 2022 Mar; 9(3):184-185. PubMed ID: 35151411
[No Abstract] [Full Text] [Related]
18. Placebo effects. Concept of placebo should be discarded.
Gotzsche PC
BMJ; 1995 Dec; 311(7020):1640-1. PubMed ID: 8555825
[No Abstract] [Full Text] [Related]
19. Correction to: Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.
Schizophr Bull; 2023 Mar; 49(2):534-537. PubMed ID: 36315443
[No Abstract] [Full Text] [Related]
20. Placebo in clinical trials.
Gupta U; Verma M
Perspect Clin Res; 2013 Jan; 4(1):49-52. PubMed ID: 23533982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
